- Investment Momentum: Closed $1.1B YTD in investments at 8.9% yield, with $360M pipeline, 50%+ in UK care homes.
- FFO/FAD Growth: Normalized FFO up 38% ($107.4M) and FAD up 33% ($107.6M), per-share growth at 14–12% YoY.
- Liquidity & Guidance: $70M cash, $850M credit facility, $879M ATM capacity; raised 2026 FFO/share guidance to $1.91–$2.01.
- Strategic Positioning: Dual investment-grade rating, 50-bps cap-rate compression in SHOP, targeting low double-digit IRR across markets.
- Debt & Growth Plans: Potential USD-denominated debt issuance; sustained double-digit FAD growth outlook across all three growth segments.
Investment Pipeline & Yields
Year‑to‑date, CareTrust has closed roughly $1.1 billion in deals at an 8.9% yield, with an additional $865 million added since April. The pipeline now stands at $360 million, more than half of which is anchored in UK care homes—an area where yields remain stable despite mild competition. The company’s off‑market sourcing and deep operator relationships enable it to lock in attractive yields early, reinforcing its portfolio quality.
Deal Flow & Growth Engines
CareTrust’s tri‑segment growth model—Skilled Nursing (SHOP), Home Health (SHOP), and Care Homes—continues to deliver steady deal flow. The skilled nursing segment remains active, driven by both brokered and proprietary opportunities, while the UK care home pipeline offers significant upside. Recent acquisition of 110 assisted‑living units in Prescott, AZ, exemplifies the firm’s ability to secure high‑yield, operator‑centric assets.
Capital Structure & Credit Rating
The recent upgrade to an investment‑grade rating by Moody’s, coupled with a $1.36 Net Debt/EBITDA ratio, positions CareTrust to tap into high‑grade debt markets this year. The company’s low cost of capital and robust liquidity give it flexibility to pursue larger portfolios and optional high‑grade market issuances, enhancing shareholder value.
Strategic Outlook & Market Opportunities
CareTrust has raised 2026 full‑year guidance, projecting normalized FFO per share of $1.91 to $2.01 and normalized FAD of $1.98 to $2.02. The firm remains agnostic on markets, targeting primary, secondary, and tertiary segments on a deal‑by‑deal basis to secure low double‑digit IRRs. Cap rates in SHOP have compressed 50 bps in the last six months, yet the firm’s operator‑centered approach and creative structuring keep it well‑positioned to capture value.
Valuation & Investor Considerations
With a dividend yield of 3.35% and a free cash flow yield of 4.07%, CareTrust offers attractive income alongside growth. The firm’s ROIC of 5.39% and ROE of 8.67% demonstrate efficient capital deployment. Investors should note the company’s strategic use of its dual investment‑grade rating and low debt leverage, which collectively underpin the current valuation multiples and provide a cushion for continued upside.